학술논문
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial
Document Type
Article
Author
Feagan, Brian G; Sands, Bruce E; Sandborn, William J; Germinaro, Matthew; Vetter, Marion; Shao, Jie; Sheng, Shihong; Johanns, Jewel; Panés, Julián; Tkachev, Alexander; Kalimullina, Dilara; Petryka, Robert; Osipenko, Marina; Tsarynna, Nataliia; Bilianskyi, Leonid; Kleczkowski, Dariusz; Yurkiv, Andrii; Woynarowski, Marek; Abrahamovych, Orest; Ivanishyn, Olha; Rydzewska, Grazyna; Kierkus, Jaroslaw; Petrova, Elina; Vasilevskaya, Olga; Afanasieva, Halyna; Francesconi, Carlos; Leszczyszyn, Jaroslaw; Bunkova, Elena; Platonov, Dmitry; Datsenko, Olena; Gridnyev, Oleksii; Hospodarsky, Ihor; Prystupa, Liudmyla; Stanislavchuk, Mykola; Pershko, Anatoly; Shchukina, Oksana; Simanenkov, Vladimir; Golovchenko, Oleksandr; Holderman, William; Lasa, Juan; Begun, Jakob; de Lourdes de Abreu Ferrari, Maria; Lopez, Pedro; Obrezan, Andrey; Farooq, Shiraz; Tiongco, Felix; Novillo, Abel; Tron, Emiliano; Macrae, Finlay; Leong, Rupert; Yukie Sassaki, Ligia; Zaltman, Cyrla; Kaiser Junior, Roberto; Stallmach, Andreas; Klaus, Jochen; Martinez, Manuel; Ruiz, Azalia; Abdulkhakov, Rustem; Sharma, Vishvinder; Korman, Louis; Lord, James; Patel, Bhaktasharan; Ritter, Timothy
Source
The Lancet Gastroenterology & Hepatology; April 2023, Vol. 8 Issue: 4 p307-320, 14p
Subject
Language
ISSN
24681253
Abstract
Despite the introduction of new monoclonal antibodies and oral therapies for the treatment of ulcerative colitis, clinical remission rates remain low, underscoring the need for innovative treatment approaches. We assessed whether guselkumab plus golimumab combination therapy was more effective for ulcerative colitis than either monotherapy.